Business Standard

SPONSORED CONTENT

What's this ?

Sponsored Content is a "Paid For" Press Release distribution arrangement. Purely a Commercial Arrangement, brands and advertisers pay to be featured and to get this content published.

The Editorial/Content team at Business Standard has not contributed to writing/editing this article.

To get your brand featured in this Section write to assist@bsmail.in

Issar Pharma develops first-ever peptide molecule for skin care

ANI Press Release 

Tennis player James Blake
Ramakrishna Reddy Isanaka

Hyderabad (Telangana) [India], October 15 (ANI/NewsVoir): India's first ever peptide molecule for the treatment of Vitiligo was developed way back in 2004 and the second peptide New Chemical Entity (NCE) which is first ever peptide-based drug in the world to treat burn wounds and microbial infections.

Issar Pharma Pvt Ltd was established in 1995 by Ramakrishna Reddy Isanaka with prime focus of research and development of New Chemical Entities (NCE) for various unmet medical needs.

The company has several patented molecules and many more life changing drugs are in the making. Peptides are proving to be effective for a multitude of diseases which includes type-2 diabetes, irritable bowel syndrome, acromegaly and cancers like breast cancer, prostate cancer, etc.

Notable Achievements of Issar Pharma

Melgain: Melgain was the first medicine invented by Issar Pharma to cure the disease of Vitiligo. Vitiligo is a condition in which the skin loses its pigment cells (melanocytes). This can result in white patches in different areas of the body, including the skin, hair and mucous membranes.

Witnessing the success and potential of Melgain, renowned pharma giant Zydus came forward to market the same under its brand name.

Xylentra: Xylentra is a highly effective medicine for second-degree burn wounds which has been patented in USA and India. Xylentra is the brand name for an ointment containing dAMP peptide which can cure the second degree burns without leaving a scar.

Cancer: Issar Pharma is working on an effective medicine to cure some of the life threatening cancers related to Prostrate, Head & Neck, Colon, Oral (solid tumors) etc. The medicine has completed Phase 1 human clinical trials successfully.

deSKAR: deSKAR brand name has been registered as topical ointment. This is patented and has the approval of regulators to manufacture and market the product.

This peptide-based ointment is a proven medicine to heal all wounds without leaving scar. It can be applied to wounds related to burns, cuts, surgical scars, diabetic etc.

Microhalt: Microhalt is a registered brand name in the form of an ointment. Microhalt is the first antimicrobial peptide which is proven in accelerated wound healing.

Psoriasis: Psoriasis is a skin disease which causes red, itchy scaly patches, most commonly on the knees, elbows, trunk and scalp. Psoriasis is a common, long-term (chronic) disease with no cure. Issar Pharma is working towards finding a cure for this skin disease.

Apart from the above, Issar Pharma is developing many more molecules with both Indian & International patents along with filings with US FDA.

Ramakrishna Reddy Isanaka completed his MS in USA in 1973. He was the Co-founder of Shantha Biotechnics in 1993 at a time when Bio-technology was new to India. He solely established Issar Pharma in 1995 with the only aim to work in the area of peptide-based drugs when Peptide Technology was starting to find its feet in Indian Pharma Industry. He has over 25 years of experience in the development of indigenous molecules and has many patents to his credit.

This story is provided by NewsVoir. ANI will not be responsible in any way for the content of this article. (ANI/NewsVoir)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, October 15 2020. 19:00 IST
RECOMMENDED FOR YOU

Issar Pharma develops first-ever peptide molecule for skin care

Hyderabad (Telangana) [India], October 15 (ANI/NewsVoir): India's first ever peptide molecule for the treatment of Vitiligo was developed way back in 2004 and the second peptide New Chemical Entity (NCE) which is first ever peptide-based drug in the world to treat burn wounds and microbial infections.

Hyderabad (Telangana) [India], October 15 (ANI/NewsVoir): India's first ever peptide molecule for the treatment of Vitiligo was developed way back in 2004 and the second peptide New Chemical Entity (NCE) which is first ever peptide-based drug in the world to treat burn wounds and microbial infections.

Issar Pharma Pvt Ltd was established in 1995 by Ramakrishna Reddy Isanaka with prime focus of research and development of New Chemical Entities (NCE) for various unmet medical needs.

The company has several patented molecules and many more life changing drugs are in the making. Peptides are proving to be effective for a multitude of diseases which includes type-2 diabetes, irritable bowel syndrome, acromegaly and cancers like breast cancer, prostate cancer, etc.

Notable Achievements of Issar Pharma

Melgain: Melgain was the first medicine invented by Issar Pharma to cure the disease of Vitiligo. Vitiligo is a condition in which the skin loses its pigment cells (melanocytes). This can result in white patches in different areas of the body, including the skin, hair and mucous membranes.

Witnessing the success and potential of Melgain, renowned pharma giant Zydus came forward to market the same under its brand name.

Xylentra: Xylentra is a highly effective medicine for second-degree burn wounds which has been patented in USA and India. Xylentra is the brand name for an ointment containing dAMP peptide which can cure the second degree burns without leaving a scar.

Cancer: Issar Pharma is working on an effective medicine to cure some of the life threatening cancers related to Prostrate, Head & Neck, Colon, Oral (solid tumors) etc. The medicine has completed Phase 1 human clinical trials successfully.

deSKAR: deSKAR brand name has been registered as topical ointment. This is patented and has the approval of regulators to manufacture and market the product.

This peptide-based ointment is a proven medicine to heal all wounds without leaving scar. It can be applied to wounds related to burns, cuts, surgical scars, diabetic etc.

Microhalt: Microhalt is a registered brand name in the form of an ointment. Microhalt is the first antimicrobial peptide which is proven in accelerated wound healing.

Psoriasis: Psoriasis is a skin disease which causes red, itchy scaly patches, most commonly on the knees, elbows, trunk and scalp. Psoriasis is a common, long-term (chronic) disease with no cure. Issar Pharma is working towards finding a cure for this skin disease.

Apart from the above, Issar Pharma is developing many more molecules with both Indian & International patents along with filings with US FDA.

Ramakrishna Reddy Isanaka completed his MS in USA in 1973. He was the Co-founder of Shantha Biotechnics in 1993 at a time when Bio-technology was new to India. He solely established Issar Pharma in 1995 with the only aim to work in the area of peptide-based drugs when Peptide Technology was starting to find its feet in Indian Pharma Industry. He has over 25 years of experience in the development of indigenous molecules and has many patents to his credit.

This story is provided by NewsVoir. ANI will not be responsible in any way for the content of this article. (ANI/NewsVoir)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
image
Business Standard
177 22

Issar Pharma develops first-ever peptide molecule for skin care

Hyderabad (Telangana) [India], October 15 (ANI/NewsVoir): India's first ever peptide molecule for the treatment of Vitiligo was developed way back in 2004 and the second peptide New Chemical Entity (NCE) which is first ever peptide-based drug in the world to treat burn wounds and microbial infections.

Issar Pharma Pvt Ltd was established in 1995 by Ramakrishna Reddy Isanaka with prime focus of research and development of New Chemical Entities (NCE) for various unmet medical needs.

The company has several patented molecules and many more life changing drugs are in the making. Peptides are proving to be effective for a multitude of diseases which includes type-2 diabetes, irritable bowel syndrome, acromegaly and cancers like breast cancer, prostate cancer, etc.

Notable Achievements of Issar Pharma

Melgain: Melgain was the first medicine invented by Issar Pharma to cure the disease of Vitiligo. Vitiligo is a condition in which the skin loses its pigment cells (melanocytes). This can result in white patches in different areas of the body, including the skin, hair and mucous membranes.

Witnessing the success and potential of Melgain, renowned pharma giant Zydus came forward to market the same under its brand name.

Xylentra: Xylentra is a highly effective medicine for second-degree burn wounds which has been patented in USA and India. Xylentra is the brand name for an ointment containing dAMP peptide which can cure the second degree burns without leaving a scar.

Cancer: Issar Pharma is working on an effective medicine to cure some of the life threatening cancers related to Prostrate, Head & Neck, Colon, Oral (solid tumors) etc. The medicine has completed Phase 1 human clinical trials successfully.

deSKAR: deSKAR brand name has been registered as topical ointment. This is patented and has the approval of regulators to manufacture and market the product.

This peptide-based ointment is a proven medicine to heal all wounds without leaving scar. It can be applied to wounds related to burns, cuts, surgical scars, diabetic etc.

Microhalt: Microhalt is a registered brand name in the form of an ointment. Microhalt is the first antimicrobial peptide which is proven in accelerated wound healing.

Psoriasis: Psoriasis is a skin disease which causes red, itchy scaly patches, most commonly on the knees, elbows, trunk and scalp. Psoriasis is a common, long-term (chronic) disease with no cure. Issar Pharma is working towards finding a cure for this skin disease.

Apart from the above, Issar Pharma is developing many more molecules with both Indian & International patents along with filings with US FDA.

Ramakrishna Reddy Isanaka completed his MS in USA in 1973. He was the Co-founder of Shantha Biotechnics in 1993 at a time when Bio-technology was new to India. He solely established Issar Pharma in 1995 with the only aim to work in the area of peptide-based drugs when Peptide Technology was starting to find its feet in Indian Pharma Industry. He has over 25 years of experience in the development of indigenous molecules and has many patents to his credit.

This story is provided by NewsVoir. ANI will not be responsible in any way for the content of this article. (ANI/NewsVoir)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22